Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
BetterLife Pharma Inc.
High return on equity (267.0%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
BetterLife Pharma Inc. shows limited reported revenue, and 267.0% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001464165, latest 10-Q filed 2019-06-17) · EODHD · rules-based read · as of 6/18/2026, 12:43:08 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY13 | FY15 | FY16 | FY17 | FY18 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | -$117K | -$10.3M | -$6.02M | -$1.05M |
| Net income | $341K | -$1.13M | -$10.3M | -$6.28M | -$121K |
| Diluted EPS | — | — | -$0.13 | -$0.08 | $0.00 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median